A phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2520-2526

  Adjei, Alex A ^a   Croghan, Gary A ^a   Erlichman, Charles ^a   Marks, Randolph S ^a   Reid, Joel M ^a   Sloan, Jeff A ^a   Pitot, Henry C ^a   Alberts, Steven R ^a   Goldberg, Richard M ^a   Hanson, Lorelei J ^a   Bruzek, Laura M ^a   Atherton, Pamela ^a   Thibault, Alain ^b   Palmer, Peter A ^b   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE; LAMIN A; TIPIFARNIB;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HUMAN; INFUSION; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROLYTES; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASMS; QUINOLONES; TIME FACTORS;

EID: 12444301731     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Clarke, S. Protein isoprenylation and methylation at carboxyl terminal cysteine residues. Annu. Rev. Biochem., 61: 355-386, 1992.
2. James, G. L., Goldstein, J. L., Pathak, R. K., Anderson, R. G., and Brown, M. S. PxF, a prenylated protein of peroxisomes. J. Biol. Chem., 269: 14182-14190, 1994.
3. Farnsworth, C. C., Wolda, S. L., Gelb, M. H., and Glomset, J. A. Human lamin B contains a farnesylated cysteine residue. J. Biol. Chem., 264: 20422-20429, 1989.
4. Sinensky, M., Fantle, K., Trujillo, M. A., McLain, T., Kupfer, A., and Dalton, M. The processing pathway of prelamin A. J. Cell Sci., 107: 61-67, 1994.
5. Reuter, C. W. M., Morgan, M. A., and Bergman, L. Targeting Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood, 96: 1655-1669, 2000.
6. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
7. Downward, J. Ras signaling and apoptosis. Curr. Opin. Genet. Dev., 8: 9-54, 1998.
8. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der, C. J. Isoprenoid addition to Ras proteins is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 89: 6403-6407, 1992.
9. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
10. Cox, A. D., and Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta, 1333: F51-F71, 1997.
11. Adjei, A. A. Protein farnesyl transferase as a target for the development of anticancer agents. Drugs of the Future, 25: 1069-1079, 2000
12. Adjei, A. A. Farnesyltransferase inhibitors. In: Amsterdam, R. Schlisky and G. Giaccone (eds.), Cancer Chemotherapy and Biologic Response Modifiers, Annual 19, pp. 177-203. Elsevier Science (Amsterdam), 2001.
13. Lebowitz, P. F., and Prendergast, G. C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene, 17: 1439-1445, 1998.
14. Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., and Cheng, J. Q. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol., 20: 139-148, 2000.
15. Ashar, H. R., James, L., Gray, K., Carr, D., Black, S., Armstrong, L., Bishop, W. R., and Kirschmeier, P. FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem., 275: 30451-30457, 2000.
16. Karp, J. E., Kaufmann, S. H., Adjei, A. A., Lancet, J. E., Wright, J. J., and End, D. W. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol., 13: 470-476, 2001.
17. Karp, J. E., Lancet, J. E., Kaufmann, S. H. End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., Ange, D., Buddharaju, L. Gojo, I., Highsmith, W. E., Belly, R. T., Hohl, R. J., Rybak, M. E., Thibault, A. and Rosenblatt, J. Clinical and biologic activity of farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical trial. Blood, 97: 3361-3369, 2001.
18. Johnston, S., Ellis, P., Houston, S., Hickish, T., Howes, A., Palmer, P., and Horak, I. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 19: 839, 2000.
19. Adjei, A. A., Davis, J. N., Bruzek, L., Erlichman, C., and Kaufmann, S. H. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cell lines. Clin. Cancer Res., 7: 1438-1445, 2001.
20. Sun, J., Blaskovich, M. A., Knowles, D., Qian, Y., Ohkanda, J., Bailey, R. D., Hamilton, A. D., and Sebtj, S. M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin. Taxol, and gemcitabine. Cancer Res., 59: 4919-4926, 1999.
21. Ratain, M. J., Mick, R., Schilsky, R. L., and Siegler, M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J. Natl. Cancer Inst. (Bethesda), 85: 1637-1643, 1993.
22. Adjei, A. A., Erlichman, C., Davis, J. N., Cutler, D. L., Sloan, J. A., Marks, R. S., Hanson, L. J., Svingen, P. A., Atherton, P., Bishop, W. R., Kirschmeier, P., and Kaufmann, S. H. A. phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res., 60: 1871-1877, 2000.
23. Inglese, J., Glickman, J. F., Lorenz, W., Caron, M. G., and Lefkowitz, R. J. Isoprenylation of a protein kinase. Requirement of farnesylation/alpha-carboxyl methylation for full enzymatic activity of rhodopsin kinase. J. Biol. Chem., 267: 1422-1425, 1992.
24. Lai, R. K., Perez-Sala, D., Canada, F. J., and Rando, R. R. The gamma subunit of transducin is farnesylated. Proc. Natl. Acad. Sci. USA, 87: 7673-7677, 1990.
25. Adjei, A. A., Davis, J. N., Erlichman, C., Svingen, P. A., and Kaufmann, S. H. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res., 6: 2318-2325, 2000.
26. Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., and Vokes, E. E. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small cell lung cancer. J. Clin. Oncol., 21: 1760-1766, 2003.
27. Macdonald, J. S., Chansky, K., Whitehead, R., Wade, J., Giguere, J., and Abbruzzese, J. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc. Am. Soc. Clin. Oncol., 21: 138a, 2002.
28. Cunningham, D., de Gramont, A., Scheithauer, Smakal, M., Humblet, Y., Kurteva, G., Iverson, T., Andre, T., Dostalva, J., Illes, A., et al. Randomized double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra™) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 21: 126a, 2002.
29. Cloughesy, T. F., Kuhn, J., Wen, P., Chan, S. M., Schiff, D., Greenberg, H., Junck, L., Robins, I., DeAngelis, L. M., Yung, A., et al. Phase II of trial R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol., 21: 80a, 2002.
30. Crul, M., de Klerk, G. J., Swart, M., van't Veer, L. J., de Jong, D., Boerrigter, L., Palmer, P. A., Bol, C. J., Tan, H., de Gast, G. C., Beijnen, J. H., and Schellens, J. H. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol., 20: 2726-2735, 2002.
31. Patnik, A., Eckhardt, S., Itzbicka, E., Hidalgo, M., McCreery, H., Mori, M., Terada, K., Tolcher, A., Smith, L., Britten, C., et al. A phase I and pharmacokinetic study of the farnesytransferase inhibitor, R115777 in combination with gemcitabine. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 19: 3a, 2000.
32. Guchelaar, H. J., Richel, D. J., and van Knapen, A. Clinical, toxicological and pharmacologic aspects of gemcitabine. Cancer Treat. Rev., 22: 15-31, 1996.
33. Joly, F., Heron, J. F., Kerbrat, P., Chauvergne, J., Rios, M., Mayer, F., Chint-Charrot, P., Goupil, A., Lebrun-Jezekova, D., Vennin, D., Lhomme, C., Mace-Lesec'h, J., and Crouet, H. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol. Oncol., 78: 361-368, 2000.